Pharmaceutical Research and Manufacturers of America
The Pharmaceutical Research and Manufacturers of America (PhRMA) is a leading trade association based in the United States, representing the innovative biopharmaceutical industry. Founded in 1958, PhRMA advocates for policies that foster medical innovation and improve patient access to life-saving medications. With a strong presence across major operational regions in the US, PhRMA focuses on key areas such as drug discovery, development, and market access. PhRMA's core services include research advocacy, policy development, and educational initiatives aimed at promoting the value of pharmaceuticals. The organisation is recognised for its commitment to advancing public health through innovation, evidenced by its members' contributions to groundbreaking therapies and vaccines. As a prominent voice in the biopharmaceutical sector, PhRMA plays a crucial role in shaping the future of healthcare and ensuring that patients benefit from the latest medical advancements.
DitchCarbon Score
How does Pharmaceutical Research and Manufacturers of America's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Membership Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmaceutical Research and Manufacturers of America's score of 36 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharmaceutical Research and Manufacturers of America's reported carbon emissions
In 2023, the Pharmaceutical Research and Manufacturers of America reported total carbon emissions of approximately 89,052,000 kg CO2e for Scope 1 and 74,164,000 kg CO2e for Scope 2, resulting in a combined total of about 162,999,000 kg CO2e for these scopes. This marks a slight decrease from 2022, where Scope 1 emissions were about 89,551,000 kg CO2e and Scope 2 emissions were approximately 82,347,000 kg CO2e, leading to a total of around 171,898,000 kg CO2e. The organisation has set ambitious climate commitments, aiming for a near-zero reduction in Scope 1 and 2 emissions by 2025. Specifically, they are targeting a 46% absolute reduction in these emissions from a 2019 baseline by 2030. Additionally, they have committed to reducing upstream logistics emissions by 10% and business travel emissions by 25% by 2025, both from a 2019 baseline. The data presented is not cascaded from any parent organisation, indicating that these figures and commitments are independently reported by the Pharmaceutical Research and Manufacturers of America.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 794,000 | 000,000 | 000,000 | 000,000 | 000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 7,903,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 17,046,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmaceutical Research and Manufacturers of America is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
